Literature DB >> 31295753

Oral keratosis of unknown significance shares genomic overlap with oral dysplasia.

Alessandro Villa1,2, Glenn J Hanna3, Alec Kacew3, Jennifer Frustino4, Peter S Hammerman3, Sook-Bin Woo1,2.   

Abstract

OBJECTIVES: To identify molecular characteristics of keratosis of unknown significance and to nominate pathways of molecular progression to oral cancer. Our work could provide a rationale for monitoring and treating these lesions definitively.
METHODS: Patients with oral leukoplakia were eligible for our prospective observational study. We correlated alterations in cancer-associated genes with clinical and histopathologic variables (keratosis of unknown significance vs. moderate-to-severe dysplasia) and compared these alterations to a previously molecularly characterized oral cancer population.
RESULTS: Of 20 enrolled patients, 13 (65%) had evidence of keratosis of unknown significance, while seven (35%) had dysplasia. Nine patients (45%) developed oral cancer (4/13 with keratosis of unknown significance, 5/7 with dysplasia). At a median follow-up of 67 (range 22-144) months, median overall survival was significantly shorter for patients with dysplasia (hazard ratio 0.11, p = .02). KMT2C and TP53 alterations were most frequent (75% and 35%, respectively). There were molecular similarities between keratosis of unknown significance and dysplasia patients, with no significant differences in mutational frequency among genes with ≥15% rate of alteration.
CONCLUSIONS: Among patients with leukoplakia, both patients with keratosis of unknown significance and patients with dysplasia developed oral cancer. Molecular alterations between these two groups were similar at this sample size.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.

Entities:  

Keywords:  dysplasia; keratosis of unknown significance; leukoplakia; oral cancer; precancerous lesions

Year:  2019        PMID: 31295753     DOI: 10.1111/odi.13155

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  7 in total

1.  Immunohistochemical staining patterns of p53 predict the mutational status of TP53 in oral epithelial dysplasia.

Authors:  Keisuke Sawada; Shuji Momose; Ryutaro Kawano; Masakazu Kohda; Tarou Irié; Kenji Mishima; Takahiro Kaneko; Norio Horie; Yasushi Okazaki; Morihiro Higashi; Jun-Ichi Tamaru
Journal:  Mod Pathol       Date:  2021-08-17       Impact factor: 7.842

2.  Podoplanin Expression Independently and Jointly with Oral Epithelial Dysplasia Grade Acts as a Potential Biomarker of Malignant Transformation in Oral Leukoplakia.

Authors:  Luís Monteiro; Barbas do Amaral; Leonor Delgado; Fernanda Garcês; Filomena Salazar; José Júlio Pacheco; Carlos Lopes; Saman Warnakulasuriya
Journal:  Biomolecules       Date:  2022-04-19

3.  Benign Alveolar Ridge Keratosis: Clinical and Histopathologic Analysis of 167 Cases.

Authors:  Asma Almazyad; Chia-Cheng Li; Sook-Bin Woo
Journal:  Head Neck Pathol       Date:  2020-03-16

4.  Gingival Leukoplakia: Hyperkeratosis with Epithelial Atrophy Is A Frequent Histopathologic Finding.

Authors:  Lama Alabdulaaly; Asma Almazyad; Sook-Bin Woo
Journal:  Head Neck Pathol       Date:  2021-05-31

5.  Architectural Alterations in Oral Epithelial Dysplasia are Similar in Unifocal and Proliferative Leukoplakia.

Authors:  Chia-Cheng Li; Soulafa Almazrooa; Ingrid Carvo; Alfonso Salcines; Sook-Bin Woo
Journal:  Head Neck Pathol       Date:  2020-09-16

6.  Recurrence in Oral Premalignancy: Clinicopathologic and Immunohistochemical Analysis.

Authors:  Maria Georgaki; Dimitris Avgoustidis; Vasileios Ionas Theofilou; Evangelia Piperi; Efstathios Pettas; Demos G Kalyvas; Dimitrios Vlachodimitropoulos; Christos Perisanidis; Andreas C Lazaris; Nikolaos G Nikitakis
Journal:  Diagnostics (Basel)       Date:  2021-05-12

Review 7.  Malignant Transformation Rate of Non-reactive Oral Hyperkeratoses Suggests an Early Dysplastic Phenotype.

Authors:  Ivan J Stojanov; Sook-Bin Woo
Journal:  Head Neck Pathol       Date:  2021-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.